These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

480 related items for PubMed ID: 27687621

  • 1. Ofatumumab in two pediatric nephrotic syndrome patients allergic to rituximab.
    Vivarelli M, Colucci M, Bonanni A, Verzani M, Serafinelli J, Emma F, Ghiggeri G.
    Pediatr Nephrol; 2017 Jan; 32(1):181-184. PubMed ID: 27687621
    [Abstract] [Full Text] [Related]

  • 2. Human or Chimeric Monoclonal Anti-CD20 Antibodies for Children with Nephrotic Syndrome: A Superiority Randomized Trial.
    Ravani P, Colucci M, Bruschi M, Vivarelli M, Cioni M, DiDonato A, Cravedi P, Lugani F, Antonini F, Prunotto M, Emma F, Angeletti A, Ghiggeri GM.
    J Am Soc Nephrol; 2021 Oct; 32(10):2652-2663. PubMed ID: 34544820
    [Abstract] [Full Text] [Related]

  • 3. [Mycophenolate mofetil in treatment of childhood nephrotic syndrome--preliminary report].
    Kwinta-Rybicka J, Wilkosz K, Wierzchowska-Słowiacze EK, Ogarek I, Moczulska A, Stec Z, Pełkowska A, Sancewicz-Pach K, Pietrzyk JA.
    Przegl Lek; 2006 Oct; 63 Suppl 3():44-8. PubMed ID: 16898486
    [Abstract] [Full Text] [Related]

  • 4. Long-term outcome of Japanese children with complicated minimal change nephrotic syndrome treated with mycophenolate mofetil after cyclosporine.
    Fujinaga S, Hirano D, Nishino T, Umeda C, Watanabe Y, Nakagawa M.
    Pediatr Nephrol; 2019 Nov; 34(11):2417-2421. PubMed ID: 31435725
    [Abstract] [Full Text] [Related]

  • 5. Mycophenolate mofetil in steroid/cyclosporine-dependent/resistant nephrotic syndrome.
    Mendizábal S, Zamora I, Berbel O, Sanahuja MJ, Fuentes J, Simon J.
    Pediatr Nephrol; 2005 Jul; 20(7):914-9. PubMed ID: 15891923
    [Abstract] [Full Text] [Related]

  • 6. Randomised controlled trial comparing ofatumumab to rituximab in children with steroid-dependent and calcineurin inhibitor-dependent idiopathic nephrotic syndrome: study protocol.
    Ravani P, Bonanni A, Ghiggeri GM.
    BMJ Open; 2017 Mar 17; 7(3):e013319. PubMed ID: 28314744
    [Abstract] [Full Text] [Related]

  • 7. [Mycophenolate mofetil versus cyclosporine A in children with primary refractory nephrotic syndrome].
    Geng HY, Ji LN, Chen CY, Tu J, Li HR, Bao R, Lin Y.
    Zhonghua Er Ke Za Zhi; 2018 Sep 02; 56(9):651-656. PubMed ID: 30180402
    [Abstract] [Full Text] [Related]

  • 8. [Multicenter survey of diagnostic and therapeutic status in Chinese childhood patients with steroid-sensitive, relaping/steroid-dependent nephrotic syndrome].
    Working Group For National Survey On Status Of Diagnosis And Treatment Of Childhood Renal Diseases.
    Zhonghua Er Ke Za Zhi; 2014 Mar 02; 52(3):194-200. PubMed ID: 24824389
    [Abstract] [Full Text] [Related]

  • 9. Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy.
    Benz K, Dötsch J, Rascher W, Stachel D.
    Pediatr Nephrol; 2004 Jul 02; 19(7):794-7. PubMed ID: 15071769
    [Abstract] [Full Text] [Related]

  • 10. Cyclosporine versus mycophenolate mofetil for maintenance of remission of steroid-dependent nephrotic syndrome after a single infusion of rituximab.
    Fujinaga S, Someya T, Watanabe T, Ito A, Ohtomo Y, Shimizu T, Kaneko K.
    Eur J Pediatr; 2013 Apr 02; 172(4):513-8. PubMed ID: 23271494
    [Abstract] [Full Text] [Related]

  • 11. Ofatumumab in Rituximab-Resistant and Rituximab-Intolerant Patients With Primary Membranous Nephropathy: A Case Series.
    Podestà MA, Trillini M, Portalupi V, Gennarini A, Tomatis F, Villa A, Perna A, Rubis N, Remuzzi G, Ruggenenti P.
    Am J Kidney Dis; 2024 Mar 02; 83(3):340-349.e1. PubMed ID: 37777061
    [Abstract] [Full Text] [Related]

  • 12. Adverse events linked with the use of chimeric and humanized anti-CD20 antibodies in children with idiopathic nephrotic syndrome.
    Bonanni A, Calatroni M, D'Alessandro M, Signa S, Bertelli E, Cioni M, Di Marco E, Biassoni R, Caridi G, Ingrasciotta G, Bertelli R, Di Donato A, Bruschi M, Canepa A, Piaggio G, Ravani P, Ghiggeri GM.
    Br J Clin Pharmacol; 2018 Jun 02; 84(6):1238-1249. PubMed ID: 29436729
    [Abstract] [Full Text] [Related]

  • 13. Three year outcome of childhood idiopathic nephrotic syndrome under a unified immunosuppressive protocol.
    Hibino S, Uemura O, Nagai T, Yamakawa S, Iwata N, Ito H, Nakano M, Tanaka K.
    Pediatr Int; 2015 Jun 02; 57(1):85-91. PubMed ID: 25225083
    [Abstract] [Full Text] [Related]

  • 14. Maintenance therapy with mycophenolate mofetil after rituximab in pediatric patients with steroid-dependent nephrotic syndrome.
    Ito S, Kamei K, Ogura M, Sato M, Fujimaru T, Ishikawa T, Udagawa T, Iijima K.
    Pediatr Nephrol; 2011 Oct 02; 26(10):1823-8. PubMed ID: 21556716
    [Abstract] [Full Text] [Related]

  • 15. Long-term effects of cyclosporine in children with idiopathic nephrotic syndrome: a single-centre experience.
    El-Husseini A, El-Basuony F, Mahmoud I, Sheashaa H, Sabry A, Hassan R, Taha N, Hassan N, Sayed-Ahmad N, Sobh M.
    Nephrol Dial Transplant; 2005 Nov 02; 20(11):2433-8. PubMed ID: 16204303
    [Abstract] [Full Text] [Related]

  • 16. Positive role of rituximab in switching from cyclosporine to mycophenolate mofetil for children with high-dose steroid-dependent nephrotic syndrome.
    Fujinaga S, Sakuraya K, Yamada A, Urushihara Y, Ohtomo Y, Shimizu T.
    Pediatr Nephrol; 2015 Apr 02; 30(4):687-91. PubMed ID: 25576066
    [Abstract] [Full Text] [Related]

  • 17. Long-term outcomes after early treatment with rituximab for Japanese children with cyclosporine- and steroid-resistant nephrotic syndrome.
    Fujinaga S, Nishino T, Umeda C, Tomii Y, Watanabe Y, Sakuraya K.
    Pediatr Nephrol; 2019 Feb 02; 34(2):353-357. PubMed ID: 30426219
    [Abstract] [Full Text] [Related]

  • 18. Tacrolimus can induce remission in cyclosporine and mycophenolate mofetil resistant pediatric onset nephrotic syndrome.
    Ahmed HM.
    Iran J Kidney Dis; 2019 Sep 02; 13(5):322-327. PubMed ID: 31705749
    [Abstract] [Full Text] [Related]

  • 19. Low-dose ofatumumab for rituximab-resistant nephrotic syndrome.
    Bonanni A, Rossi R, Murtas C, Ghiggeri GM.
    BMJ Case Rep; 2015 Sep 16; 2015():. PubMed ID: 26376698
    [Abstract] [Full Text] [Related]

  • 20. Rituximab in Children with Steroid-Dependent Nephrotic Syndrome: A Multicenter, Open-Label, Noninferiority, Randomized Controlled Trial.
    Ravani P, Rossi R, Bonanni A, Quinn RR, Sica F, Bodria M, Pasini A, Montini G, Edefonti A, Belingheri M, De Giovanni D, Barbano G, Degl'Innocenti L, Scolari F, Murer L, Reiser J, Fornoni A, Ghiggeri GM.
    J Am Soc Nephrol; 2015 Sep 16; 26(9):2259-66. PubMed ID: 25592855
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.